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Pilocytic astrocytoma (PA) is the most frequently encountered glial tumor (glioma or astrocytoma) in children. Recent studies
have identiﬁed alterations in the BRAF serine/threonine kinase gene as the likely causative mutation in these childhood brain
tumors. The majority of these genetic changes involve chromosome 7q34 tandem duplication, resulting in aberrant BRAF fusion
transcripts. In this paper, we describe a novel KIAA1549:BRAF fusion transcript in a sporadic PA tumor associated with increased
ERK activation and review the spectrum of BRAF genetic alterations in this common pediatric low-grade central nervous system
neoplasm.
1.Introduction
Pilocytic astrocytomas are the most common nonmalignant
brain tumor in the pediatric population. Children with the
Neuroﬁbromatosis type 1 (NF1) inherited cancer predispo-
sition syndrome are prone to the development of these glial
cell neoplasms, such that 15–20% of aﬀected individuals will
develop gliomas involving the optic pathway, hypothalamus,
and brainstem [1]. Molecular analysis of these tumors has
revealed biallelic inactivation of the NF1 tumor suppressor
gene, resulting in loss of NF1 protein (neuroﬁbromin)
expression. However, sporadic PA tumors do not exhibit
mutational inactivation of the NF1 gene, suggesting that
other genetic mutations are responsible for the genesis of
these histologically-identical low-grade brain tumors in the
general population [2].
Over the past several years, the molecular basis for these
nonsyndromic pediatric brain cancers has been elucidated
with the identiﬁcation of signature molecular changes
involving the BRAF serine/threonine kinase gene. The most
frequently encountered genetic alteration is a tandem dupli-
cation of the BRAF gene on chromosome 7q34, leading
to fusion of the KIAA1549 gene to the carboxyl terminal
region of the BRAF gene containing the kinase domain. This
molecular change has been reported in 50–65% of sporadic
pilocytic astrocytoma and is more frequent in cerebellar
(∼80%) tumors. The majority of these alterations involve
fusions between KIAA1549 exon 16 and BRAF exon 9,
KIAA1549 exon 15 and BRAF exon 9, and KIAA1549 exon
16 and BRAF exon 11 [3–9], while less common alterations
includetandemduplicationsinvolving SRGAP3andRAF1or
FAM131B and BRAF [10, 11]. In this paper, we describe a
novel KIAA1549-BRAF fusion event in a sporadic pediatric
pilocytic astrocytoma.
2. Case Presentation
The patient was a 14-year-old boy who presented with a
6-month history of headache that progressed to a two-day
period of nausea, vomiting, and ataxia. Magnetic resonance
imaging (MRI) at that time showed a cystic mass in the
cerebellum compressing the fourth ventricle (Figure 1(a)).
He was taken to the operating room where a gross total
resection was performed. Neuropathological review revealed
a classic pilocytic astrocytoma with alternating areas of
compact and loose tissue architecture (Figure 1(b)). The
compact areas were composed of piloid neoplastic cells
containing numerous Rosenthal ﬁbers and few eosinophilic
granular bodies (Figure 1(c)), while the paucicellular areas2 Case Reports in Medicine
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Figure 1: Molecular characterization of a novel KIAA1549:BRAF fusion alteration in a sporadic pediatric pilocytic astrocytoma. (a) Axial
T1-weighted 1.5-Tesla gadolinium-enhanced MRI scan reveals a cystic lesion in the cerebellum with a peripheral enhancing nodule (arrow).
Hematoxylin and eosin staining demonstrates a classic pilocytic astrocytoma with compact and loose areas (b), including Rosenthal ﬁbers
(arrow) and eosinophilic granular bodies (arrowhead) (c). The tumor is composed of cells with strong GFAP expression (d) and rare Ki-
67 immunoreactivity (arrowhead; (e)). Direct ampliﬁcation of RNA from this tumor demonstrates a 599 bp fragment, which creates a
novel fusion KIAA1549:BRAF transcript in which exon 16 of the KIAA1549 gene is joined to BRAF sequences in the middle of exon 10.
The bars below the predicted amino acid sequence correspond to BRAF exon 10 (red), BRAF exon 11 (green), and KIAA1549 exon 16
(blue) (f). Immunostaining with phospho-ERK-Thr202/Tyr204 antibodies demonstrates increased ERK activation in the PA tumor (bottom
panel). Normal adult human frontal lobe (NB) from an autopsy specimen was included as reference tissue in the top panel (g). Western blot
demonstrates 282-fold increase in ERK activation (phospho-ERK-Thr202/Tyr204; p-ERK; Cell Signaling Technologies, catalog no. 4370S) in
the tumor (PA) relative to normal human brain (NB). Total ERK is included as internal control for protein loading (h).Case Reports in Medicine 3
Table 1: Summary of reported BRAF fusion transcripts.
Fusion partner BRAF Number of cases % cases
KIAA1549 exon 16 exon 9 136 62.4
KIAA1549 exon 15 exon 9 47 22.6
KIAA1549 exon 11 exon 11 29 12.3
KIAA1549 exon 18 exon 10 1 <1
KIAA1549 exon 19 exon 9 1 <1
KIAA1549 exon 16 exon 10∗ 1 <1
FAM131B exon 9 3 1.4
∗Current paper.
were largely myxoid with scattered pleomorphic tumor cells,
often containing multiple nuclei. Consistent with the glial
nature of this tumor, there was diﬀuse and strong glial
ﬁbrillary acidic protein (GFAP) expression in the neoplastic
cells (Figure 1(d)). The Ki67 labeling (proliferative) index
was <1% (Figure 1(e)), and mitotic ﬁgures were not iden-
tiﬁed. Upon two-year followup, there was no evidence of
recurrenttumoronMRI.Toidentifythemolecularalteration
in this pilocytic astrocytoma, RNA was extracted from a
snap-frozen tumor specimen using the RNeasy mini-kit
(QIAGEN), reverse transcribed, and ampliﬁed by PCR using
BRAF and KIAA1549 p r i m e r sa sp r e v i o u s l yr e p o r t e d[ 8].
Both strands of the resulting novel 599 base pair (bp)
product were directly sequenced on an ABI 3730xl DNA
Analyzer.IncontrasttopreviouslyreportedKIAA1549:BRAF
alterations, this tumor harbored a novel fusion transcript in
which exon 16 of the KIAA1549 gene was fused to sequences
within exon 10 of the BRAF gene (Figure 1(f)), generating
a protein product in which the BRAF kinase domain is
intact. This would result in a molecule in which the carboxyl
terminal kinase domain is not bound by the amino terminal
BRAF regulatory domain and is thus “constitutively” active,
leading to downstream MEK and ERK activation. Consistent
with this prediction, we found increased ERK activation
usingactivation-speciﬁc(phospho-Thr202/Tyr204)antibodies
in the tumor by both immunohistochemistry (Figure 1(g))
and Western immunoblotting (Figure 1(h)).
3. Discussion
The vast majority of previously reported molecular alter-
ations in sporadic involve BRAF exons 9 (85% of reported
KIAA1549:BRAF fusiontranscripts)and11(12%ofreported
KIAA1549:BRAF transcripts) (Table 1). Similarly, all of the
FAM131B:BRAF fusion products also included BRAF exon 9
sequences [11]. The current paper describes only the second
KIAA1549:BRAF fusion event involving exon 10 [7] and is
the ﬁrst in which the alteration eliminates nearly half of the
exon 10-encoded BRAF protein sequence. The inclusion of
this speciﬁc genetic alteration to the growing list of BRAF
molecular changes supports a model in which fusion events
that maintain the BRAF open reading frame and include
the BRAF protein sequences encoded by exons 11–18 (BRAF
kinase domain) are potentially tumorigenic.
This proposed tumorigenicity is attributed to constitu-
tive activation of the BRAF kinase domain as a result of the
removal of the amino terminal inhibitory domain, leading to
increased signaling to its immediate downstream eﬀectors,
MEK and ERK. Similar to other BRAF mutations, this
novelKIAA1549:BRAF molecularalterationisalsoassociated
with increased ERK activity. However, the exact mechanism
by which deregulated MEK/ERK activation resulting from
KIAA1549:BRAF leadstopilocyticastrocytomadevelopment
is unclear. In this regard, several groups have shown that
the expression of constitutively active (oncogenic) BRAF
(BRAFV600; V600E mutation within the BRAF activation
domain) in human astrocytes and glial progenitor cells leads
to cellular senescence in vitro [12], and neither oncogenic
BRAFV600 nor RAF1 expression in mice results in glioma
formation in vivo [13, 14]. However, forced expression of
the kinase domain of BRAFV600, but not of wild-type BRAF
(as exists in KIAA1549:BRAF fusion protein products), is
transforming in primary human astrocytes in vitro and can
induce tumors in mice in vivo [13].
NF1-associated pilocytic astrocytomas also exhibit
increased ERK activation as a result of mutation loss of the
NF1 tumor suppressor protein, neuroﬁbromin. In primary
mouse astrocytes, loss of neuroﬁbromin Ras GTPase ac-
tivating protein (GAP) activity leads to high levels of Ras
eﬀector (ERK, AKT) activation. However, Nf1 genetically
engineered mouse optic glioma growth is attenuated by
inhibiting AKT pathway signaling [15]. In these studies,
inhibitionofAKT-mediatedmammaliantargetofrapamycin
(mTOR) activity using the macrolide rapamycin resulted
in reduced optic glioma volume and proliferation. In light
of these observations, the molecular mechanism shared by
BRAF activation and neuroﬁbromin loss will require further
experimental investigation.
In this regard, future studies will likewise be required
to determine precisely how BRAF activation leads to glioma
formation either alone or in concert with other genetic or
stromal (microenvironment) changes. Despite these seem-
ingly contradictory experimental observations, the identiﬁ-
cation of BRAF as a seminal genetic alteration in pilocytic
astrocytoma sets the stage for therapeutic trials aimed at
restoring deregulated BRAF/RAF signaling in this common
pediatric brain tumor.
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